Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Plans To Shed 13% Of Work Force By 2015

This article was originally published in The Pink Sheet Daily

Executive Summary

The pharma responds to a tough market environment by stepping up its previously-announced cost savings program to total $4 billion to $4.6 billion a year by 2015.

You may also be interested in...

Meet Merck’s Dealmaker: A Conversation With Roger Pomerantz

Merck’s new head of worldwide licensing and knowledge management Roger Pomerantz, MD, talks with IN VIVO about Merck’s business development strategy, whether biotech passion can exist on a Big Pharma scale, and the art of the deal.

Vertex Takes Early Lead In HCV Protease Inhibitor Sales

Incivek, launched in May, already has posted sales of $74.5 million, while Merck's competing Victrelis has tallied $21 million in sales so far.

Despite Recent Setbacks, Merck's CV Pipeline Is Strong

The Big Pharma reports better than expected first quarter revenues and discusses what is coming in R&D and the cardiovascular pipeline.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts